November 2018

SBFNL will exhibit at SfN's 48th annual neuroscience meeting, November 3-7, 2018 at San Diego Convention Center, San Diego, CA booth number 4116!

See us at SfN's 48th annual neuroscience meeting.

Past Events

November 2017

SBFNL will exhibit at SfN's 47th annual neuroscience meeting, November 11-15, 2017 at the Walter E. Washington Convention Center. Washington, DC. 

Booth number 3212!

See us at SfN's 47th annual neuroscience meeting.

November 2016

SBFNL exhibited at SfN's 46th annual neuroscience meeting, November 13-16, 2016 at San Diego Convention Center, San Diego, CA booth number 3926!

Dr Javier F. Alcudia from Gene Vector and Virus Core and Dr Andrew Olson from Neuroscience Microscopy Service joined us for the meeting this year.

See us at SfN's 46th annual neuroscience meeting.

November 2014

SBFNL exhibited at SfN's neuroscience meeting in Washington D.C.

You can also view and download our posters here: 


October 2012

LPS Induced Cognitive Impairments as a New Test Model for Cognitive Enhancers

Lipopolysaccharide (LPS) is a large molecule that prevents Gram-negative bacteria from losing structural integrity during chemical attacks. Intraperitoneal injection of LPS (at 250 μg/kg) in rodents induces a neuroinflammatory response and memory impairment determined by various behavioral measures.  It has been suggested that repeated injection with LPS results in an accumulation of Aβ1–42 in the hippocampus and cerebral cortex of mice brains through increased β- and γ-secretase activities and Alzheimer’s Disease (AD)-like acute pathology. These pathological changes are accompanied by behavioral deficits characteristic of an AD brain. At BFNL, we have established a LPS toxicity protocol followed by Fear Conditioning assessment to explore deficits in retrieval of cued and contextual memory in mice. We have shown that increasing LPS dosages elicits deficits in both contextual and cued memory retrieval in wild type C57Bl/6J mice (Figure 1). Thus, LPS toxicity in mice could be used as yet another model for testing the efficacy of experimental therapeutics and genetic models for AD and many other CNS disorders.